Results 141 to 147 of about 2,329 (147)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

Journal of Crohn's and Colitis, 2021
Stephen B Hanauer, Vivian W. Huang
exaly  

Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Advances in Therapy, 2020
Jonathan Q Tran, Liangang Liu, Peijin Zhang   +2 more
exaly  

Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator

Clinical Pharmacology in Drug Development, 2018
Jonathan Q Tran
exaly  

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects

Advances in Therapy, 2020
Sarah Harris, Jonathan Q Tran, Peijin Zhang   +2 more
exaly  

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Clinical Pharmacology in Drug Development, 2018
Jonathan Q Tran
exaly  

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator

Journal of Clinical Pharmacology, 2017
Jonathan Q Tran, Hugh Rosen
exaly  

Ozanimod for relapsing remitting multiple sclerosis and how Brexit changed the journey

Journal of Prescribing Practice, 2022
exaly